Ameliorative Effect of Ghrelin on Thyroxin Hormones and Body Weight in Hyperthyroidism Male rats

Fouad Ziedan Hamza1, Muna H. AL-Saeed1

1- Department of Physiology, Pharmacology and Chemistry, College of Veterinary Medicine, University of Basrah, Basrah, Iraq.

Corresponding Author: muna.mahmood@uobasrah.edu.iq

Received: Dec 11, 2021; Accepted: Dec. 29, 2021; Available Online, Dec. 2021

Abstract

The study's objective is to evaluate the enhanced effect of the ghrelin on the body weight and thyroid hormones in male rats after inducing hyperthyroidism by L-thyroxin. The rats (95 males) were split into two groups. The first group consisted of 25 male rats that were given normal saline for 30 days S.C and set as a control group. While the remainder of the animals were given levothyroxine 500g/kg subcutaneously for 30 days to induce hyperthyroidism. after induction the divided into 4 groups as followe ,the first one was the control group that mentioned previously, the second group was male rats were given normal saline for 30 days S.C, the third group was male rats were given ghrelin at a dose of (0.5nmol/100μl saline) for 30 days S.C, and the fourth group was male rats (1nmol/100μl saline) for 30 days S.C. The fifth group consisted of hyperthyroidism male rats that was given ghrelin at a dosage of (2nmol/100μl saline) for 30 days S.C. The results of final weight and weight gain are presented showed no significant difference in initial weight within all groups that were observed, while a significant decrease in final body weight in hyperthyroidism group compared with control group. On the other hand, the results revealed a significant decrease in body weight gain in male rats have hyperthyroidism compared with the control group. While the results observed a significant increase final body weight and body weight gain in all treated rats with ghrelin as compared with hyperthyroidism group. On other hand, the effect of hyperthyroidism on serum TSH, T3, and T4 concentrations revealed that the hyperthyroidism group had a significant rise in serum T3 and T4 concentrations when compared to the control group. While no significant drop in serum TSH concentration was observed in all hyperthyroidism groups handled with ghrelin (0.5, 1 and 2 nmol) as compared to the hyperthyroidism group, a significant decrease in serum T3 and T4 level was observed in all hyperthyroidism groups treated with ghrelin in comparison to the group of hyperthyroidism. Ghrelin peptide hormone and it has been shown to have potential effects on the body weight and thyroid hormone.

Keywords: Hyperthyroidism, ghrelin, Levothyroxine, Thyroxin, rats
**Introduction**

Hyperthyroidism is a clinical condition defined by high serum concentrations of thyroxine (T4), triiodothyronine (T3), or both, as well as a restriction of serum thyroid-stimulating hormone (TSH) concentrations [1], which results in metabolic formation and acceleration of the production of free radicals to induce changes in the activity of antioxidant enzymes. Weight loss despite increased hunger, palpitation, agitation, tremors, dyspnea, fatigability, diarrhea, or enhanced gastrointestinal motility are all symptoms of hyperthyroidism. A patient having hyperthyroidism often has signs and symptoms consistent with this condition of elevated metabolic activity [2-3].

Ghrelin is a kind of human growth hormone (GH) Secretagogue is now recognized as a pleiotropic and ubiquitous hormone engaged in a variety of metabolic activities such as appetite control and weight regulation, glucose metabolism, obesity, reproduction, memory, learn, and reward-related pathways [4-5]. Ghrelin lowers inflammation by significantly suppressing the production of inflammatory cytokines and lowering oxidative stress in a variety of organs [6].

Ghrelin receptor engages with one another in many different organs, includes the stomach, pituitary, digestive system, and thyroid [7]. According to the enzyme ghrelin O-acyltransferase, acyl ghrelin (AG) is the major active isoform in the cytoplasm (GOAT) [8]. Desacyl-grelin (DAG) was once assumed to be an inactive form of ghrelin. DAG has been linked to a variety of additional effects, but identifying potential alternative DAG receptors is crucial for understanding its distinct modes of action [9]. The different of ghrelin receptors sites offers that ghrelin has a number of natural activities [10]. It reduces energy expenditure as well as TSH secretion. Previous study has shown that ghrelin lowers pituitary-thyroid nerve center activity [11-12-13]. Ghrelin has also been shown to stimulate desire via the neuropeptide Y (NPY) and agouti related protein pathways, while decreasing T3 and T4 synthesis [11-13]. Likewise, studies have shown that ghrelin can expand the development chemical delivery [14], gastric discharging rate; hunger and body weight and furthermore invigorate the emission of adrenocorticotropic chemical and restraint of thyroid chemical fixations[15].

**Materials and Methods**

The present investigation was done at Basrah University/ Veterinary Medicine College. The study comprises two experiments a total of ninety five adult male rats (12 weeks old, weighing (250-300g) were used male rats were kept for adaptation period of one month.

**Experimental design**

First Experimental (hyperthyroidism-induce in male rat):- The rats were separated into two main groups: the first (Control group) consisted of 20 male rats. Normal saline was used to treat the control group, second group (positive group) (hyperthyroidism-induce in male rat): All the experimental animals were administered with L-thyroxine 500μg/kg body weight S/C daily for one month.

Second Experimental: After 30 days scarified ten male rats from each groups to confirm induction of hyperthyroidism. the From experiment one were divided into five main groups, each of 15 rats. control group of first experiment were administrated of s.c injection of 100 μl saline (served as control) for 30 days, second group hyperthyroidism-
induced rats administrated s.c injection of 100 μl saline (served as positive control) for 30 days, third group hyperthyroidism-induced rats were administrated Ghrelin (0.5nmol/100μl saline) s.c injection for 30 days, fourth group hyperthyroidism-induced rats were administrated Ghrelin (1nmol/100μl saline) s.c injection for 30 days, fifth group hyperthyroidism-induced rats were administrated Ghrelin (2nmol/100μl saline) s.c injection for 30 days.

**Body weight and measurement of weight gain:** The rats’ weight was measured before and after the experiment.

At the end of the treatment ten rats from each group were sacrificed, then the samples of blood were collected from inferior vena cava of the heart and the organ thyroid gland were collected and preserved in 10% formalin for histological examination [16].

**Hormonal Analysis:** TSH, T4, and T3 levels in serum samples were determined using the (ELISA) method and the Elabscience kit[17].

**Statistical Analysis**

It was performed by single direction covariance (ANOVA) test and t-test. Utilizing SPSS (measurable bundles for the sociologies) program V. 21.[18].

**Results**

**Impact of hypothyroidism on body weight and body weight gain in male rats.**

Table (1) shows that there was no significant (P>0.05) difference in beginning body weight between groups detected, however there was a significant (P<0.05) drop in final body weight in the hypothyroidism group compared to the control group. The results, on the other hand, demonstrated a substantial (P<0.05) reduction in body weight increase in hyperthyroid male rats in comparison to the control group.

**Effect of Hyperthyroidism on Serum TSH, T3 and T4 Concentration in Male Rats.**

Table (2) depicts the effect of hyperthyroidism on serum TSH, T3, and T4 concentrations, demonstrating that there was a significant (P≤0.05) rise in serum T3 and T4 concentrations in the hyperthyroidism group as compared to the control group. When compared to the control group, the hyperthyroidism group had a substantial (P≤0.05) drop in blood TSH concentrations.

**Ghrelin's Effect on Final Weight and Weight Gain in Male Rats Having Hyperthyroidism Male Rats.**

The data of body weight and body weight gain in Table (3) showed a substantial (P≤0.05) decrease in the last body weight and body weight gain of the hyperthyroidism group when compared with the control, while the results revealed a significant (P≤0.05) increase in the final body weight and body weight gain in all treated rats with ghrelin when compared with the hyperthyroidism group that the final body weight and body weight gain when treated with ghrelin in all groups.

**Effect of Ghrelin on serum TSH, T3 and T4 in Hyperthyroidism Adult Male Rats.**

Table (4) shows the impact of ghrelin on serum TSH, T3 and T4 levels. There’s a significant (P≤0.05) decrease in serum TSH concentration of the hyperthyroidism group and all treated groups with ghrelin when compared to the control group, but no significant in serum TSH concentration was noticed in all hyperthyroidism groups treated.
with ghrelin (0.5, 1 and 2 nmol) when compared to hyperthyroidism group.

Table (4) also shows that the hyperthyroidism group had a significant (P≤0.05) rise in serum T3 and T4 concentrations when compared to the control group, whereas the hyperthyroidism groups treated with ghrelin (0.5, 1 and 2 nmol) had a significant (P≤0.05) drop in serum T3 and T4 levels when compared to the hyperthyroidism group alone. There were no significant (P≤0.05) differences in serum T3 level in either of the ghrelin (1 and 2 nmol) treated groups when compared to the control group, but there was a significant (P≤0.05) increase in serum T3 in the hyperthyroidism group treated with ghrelin (0.5 nmol) when compared to the control group and other hyperthyroidism groups treated with ghrelin (1 and 2 nmol). In addition, no significant (P>0.05) differences in serum T4 concentration were observed in both hyperthyroidism groups treated with ghrelin (0.5 and 1 nmol) in comparison to the control group, while a significant (P>0.05) decrease in serum T4 was observed in the hyperthyroidism group treated with ghrelin (2 nmol) in comparison to the control group.

In contrast, a substantial (P>0.05) drop in serum T4 was found in the hyperthyroidism group handled with ghrelin (2 nmol) when compared to the hyperthyroidism group treated with ghrelin (0.5 nmol). There were no significant (P>0.05) variations in blood T4 concentrations between the hyperthyroidism group treated with ghrelin (2 nmol) as compared to the hyperthyroidism group treated with ghrelin (1 nmol). Also, no significant (P>0.05) difference was noticed in serum T4 concentrations of hyperthyroidism group treated with ghrelin (1 nmol) in comparison to the hyperthyroidism group treated with ghrelin (0.5 nmol).

Table 1: Impact of Hypothyroidism on body weight and body weight gain in male rats. (mean±SD)  N=10.

| Groups                  | Parameters       | Initiate weight (g) | Final weight (g)  | weight gain (g) |
|-------------------------|------------------|---------------------|-------------------|-----------------|
| control group           |                  | 273.68± 9.80 a      | 293.62±24.66 a    | 20.78±4.83 a    |
| Hyperthyroidism group   |                  | 273.31± 6.57 a      | 268.00± 18.26 b   | 6.44±1.98 b     |

Significant differences at the (P≤0.05) level are denoted by values in tiny letters.
Table 2: Effect of Hyperthyroidism on Serum TSH, T3 and T4 Concentration in Male Rats. (mean±SD) N=10.

| Groups           | Parameter | TSH (μU/ml) | T3 (ng/ml) | T4 (μg/dl) |
|------------------|-----------|-------------|------------|------------|
| Control          |           | 0.12±0.007a | 1.29±0.34b | 4.80±0.08b |
| Hyperthyroidism  |           | 0.03±0.012b | 2.82±0.20a | 6.25±0.80a |

Significant differences at the (P≤0.05) level are denoted by values in tiny letters.

Table 3: Ghrelin's Effect on Final Weight and Weight Gain in Male Rats Having Hyperthyroidism Male Rats. (mean±SD) N=10.

| Groups                     | Parameter     | Initial body weight(g) | Final body weight (g) | Gain body weight (g) |
|---------------------------|---------------|-------------------------|-----------------------|----------------------|
| Control                   |               | 295.50±14.59 a          | 310.50±15.40 a        | 14.00±1.26 a         |
| Hyperthyroidism           |               | 268.00±3.62 b          | 271.75±4.92 b         | 7.33±1.03 b          |
| Hyper+(0.5 nmmol) GHR     |               | 267.62±4.17 b          | 290.37±3.20 a         | 13.66±0.98 a         |
| Hyper+ (1 nmmol) GHR      |               | 266.50±4.53 b          | 291.37±2.61 a         | 13.58±0.91 a         |
| Hyper+(2 nmmol) GHR       |               | 268.00±2.07 b          | 294.00±3.85 a         | 13.91±1.02 a         |
| LSD                        |               | 7.34                   | 7.44                   | 1.24                 |

Significant differences at the (P≤0.05) level are denoted by values in tiny letters.
Table 4: Effect of Ghrelin on Serum TSH, T₃ and T₄ in Hyperthyroidism Adult Male Rats. (mean±SD) N=10.

| Groups         | Parameter | TSH (μlU/ml) | T3 (ng/ml) | T4 (μg/dl) |
|----------------|-----------|--------------|------------|------------|
| Control        | 0.17±0.018a | 1.17±0.05c   | 4.90±0.12b |
| Hyperthyroidism| 0.07±0.024b | 2.66±0.38a   | 6.26±0.49a |
| Hyper+(0.5GHR)| 0.07±0.029b | 2.05±0.15b   | 5.12±0.33b |
| Hyper+ (1 GHR)| 0.06±0.027b | 1.39±0.17c   | 4.81±0.29bc|
| Hyper+(2 GHR)| 0.07±0.029b | 1.20±0.04c   | 4.44±0.34c |
| LSD            | 0.10      | 0.24         | 0.40       |

Significant differences at the (P≤0.05) level are denoted by values in tiny letters.

Histopathological Analysis

Thyroid gland

Control rats' thyroid glands looked to have standard structure, with typical follicles (TF) of varied sizes walled by a singular epithelial cell layer and laden with emulsified colloid (C) surrounded by conventional parafollicular cells (PF), as shown in Fig. (1). Hyperthyroidism rats produced by thyroxine, on the other hand, displayed histological alterations such as disrupted and fused thyroid follicles (DF) and vacuolated cytoplasm (V) in the follicular cells, as seen in Fig (2). Whereas the histological section of the thyroid gland of hyperthyroidism rats treated with ghreline (0.5nmol/100μl saline) showed virtually standard structure consisting of varied sizes of thyroid follicles brimming with emulsified colloid and typical parafollicular cells (Fig (3)). Furthermore, as shown in Fig. 4, thyroid sections from hyperthyroidism rats treated with ghrelin (1nmol/100μl saline) revealed typical follicles packed with emulsified colloid. Eventually, the thyroid gland of hyperthyroidism pretreated with ghrelin (2nmol/100μl saline) group displays a virtually standard structure and presence, the gland consisting largely of follicles brimming with emulsified colloid and bordered by parafollicular cells, as seen in Fig. (5).
Fig. (1) Thyroid of control rat. Showing normal architecture of different sizes thyroid follicle (TF) filled with homogenized colloid (C) surrounded by normal parafollicular cells (P). (Hematoxylin-Eosin stain) 40X.

Fig. (2) Thyroid gland in hyperthyroidism male rats group. The section shows disturbed and fused thyroid follicles (DF) (Black arrow) and vacuolated cytoplasm (green arrow) can be observed in the follicular cells. (Hematoxylin-Eosin stain) 40X.

Fig. (3) Thyroid of hyperthyroidism male rats treated with ghreline (0.5nmol/100μl saline). Showing normal thyroid follicles filled with homogenized colloid (C), surrounded by normal parafollicular cells (P). (Hematoxylin-Eosin stain) 40X.

Fig. (4) Of hyperthyroidism male rats treated with ghreline (1nmol/100μl saline). Showing normal thyroid follicles filled with homogenized colloid (C), surrounded by normal parafollicular cells (P). (Hematoxylin-Eosin stain) 40X.

Fig. (5) Hyperthyroidism male rat treated with ghreline (2nmol/100μl saline). Showing normal thyroid follicles filled with homogenized colloid (C), surrounded by normal parafollicular cells (P). (Hematoxylin-Eosin stain) 40X.
Discussion

The results show that adult male rats treated with thyroxin (500µg/kg b.w/day) for 30 days had a substantial decrease in the ultimate weight and weight growth, in comparison to the control group. The findings agreed with those of Kim et al.,[19] and Ros-Prego et al.,[20]. There are several theories regarding it. Hyperthyroidism prompts an expanded basal energy consumption that prompts weight reduction because of a decline in the body's fat and fat mass [21]. When compared to the hyperthyroid group, ghrelin had a better influence on body weight and weight growth in all treatment groups. These findings are consistent with those of Delporte [22] and Akalu et al. [23]. Anti-ghrelin antibodies were found to enhance energy expenditure in laboratory mice [24]. This demonstrates ghrelin's role in energy regulation by increasing caloric intake while decreasing energy utilization [25]. The ghrelin receptors are an essential thermogenesis controller [26]. Ghrelin alerting through these receptors reduce thermogenesis, which reduces expenditure of energy [23, 27]. In addition to decreased thermogenesis, ghrelin reduces energy expenditure by lowering locomotory action [28] and decreasing the function of the thoughtfull sensory system (SNS), notably in brown fat tissue (BAT) [29]. Ghrelin stimulates preadipocyte separation, adipogenesis, inhibits adipocyte death, and irritates lipolysis in rats [28]. Ghrelin promotes increased adiposity causes weight growth in the body [30, 31] in a method that is not dependent on food [32]. Ghrelin has been demonstrated to activate particular brain areas for its function in the control of food-related behaviors [33], such as the hypothalamic arcuate(ARC), where agouti-related peptide (AgRP)/neuropeptide Y (NPY) neurones convey a negative valence signal [34], and the VTA, which contains dopamine cells that signal reward. Ghrelin reduces energy expenditure in young healthy women, according to a research [35]. In mice, recombinant proghrelin stimulates food consumption during the photoperiod by going to act on a receptor that has not been identified specific from GHSR1a, but it does not cause weight gain. It reduces respiratory rest, resulting in rise in fat utilization and energies consumption, that is in contrast to the impact of acyl ghrelin [36]. Our analysis of this result could be the ghrelin led to the reduction of thyroxine hormone and thus led to a decrease in basal energy expenditure and an increase in fat mass in the body hyperthyroidism led to increase T3 and T4 while decrease TSH, this result agreement with several investigators [37, 38, 39, 40]. This hyperthyroid state saw here was additionally upheld by the diminished body weight gains and is reliable with the expanding in catabolic movement depicted in hyperthyroidism [41, 42]. When compared to the hyperthyroidism group, ghrelin considerably lowered thyroid hormone concentrations while having no effect on TSH. These data imply that ghrelin may influence the hypothalamus-pituitary-thyroid(HPT) axis. In actuality, a recent study in male rats found that after an intracerebroventricular infusion of ghrelin or a placebo every 24 hours for 5 days, pituitary thyroid stimulating hormone cells were more reasonable and TSH plasma levels were lower, and as a result, thyroid follicles were less dynamic and thyroxin (T4) plasma levels were lower compared to placebo-treated rats [43]. Furthermore, after 20 minutes, a ghrelin injection intraventricular (ICV) infusion resulted in considerably lower TSH plasma levels than a placebo treatment [44]. Ghrelin, on the other hand, showed no influence on TSH levels in investigations on canines (15-16) and humans (17-45). Furthermore, hexarelin, a synthetic GHS-R agonist, was reported to lower TSH after a
solar dose within 2 hours [46]. Despite this, hexarelin had no long-term effect on TSH levels [46]. Other evidence suggests that ghrelin plays a control function of the HPT axis: ghrelin-restricting destinations, perhaps unique to the GHS-R, have been discovered in the human thyroid [48, 49]. Ghrelin also increased in vitro TSH-induced rat thyrocyte development [50] while decreasing cell multiplication in human thyroid cancer cell lines [49]. Our findings are consistent with those of Kordi and Khazali [51], who found that intraventricular infusion of 5 nmol ghrelin substantially lowered plasma levels of T3 and T4. In the arcuate core, ghrelin creates an amalgamation of Agouti and neuropeptide Y. [14, 52]. It is also known that Agouti and neuropeptide Y immunoreactive axons densely innervate the neurons that secrete thyrotropin-releasing hormone (TRH) in the hypothalamic paraventricular nucleus (PVN). Furthermore, exogenous intraventricular (ICV) or PVN injections of Agouti or neuropeptide Y significantly pauses HPT action [53, 54]. As a result, ghrelin may impede thyroid function by increasing Agouti or neuropeptide Y. Also, Agouti has been shown to behave as an endogenous antagonist or inverse agonist at melanocortin receptors on TRH neurons. Several studies have revealed that arcuate alpha-melanocyte-stimulating hormone (α-MSH) neurons densely innervate PVN TRH neurons. As a result, there is a significant increase in TSH and thyroid chemical levels following ICV or paraventricular infusion of α-MSH [54, 55, 56]. Thus, we may expect ghrelin to have an inhibitory influence on the HPT axis, at least partially, due to a rise in Agouti levels and its antagonist action on α-MSH receptors. It has been postulated that localized ghrelin inhibits GABA firing from (gamma aminobutyric acid) Agouti or neuropeptide Y neurons in the nerve center. Inhibiting GABA release is included in the activation of CRF neurons (corticotropin releasing factor) and the increase of corticotropin releasing hormone (CRH) from the hypothalamus [57]. Because CRH and cortisol have an inhibitory effect on plasma T3 and T4, [58, 59], inhibitory impact of ghrelin on thyroid may be somewhat causes of its stimulatory impact on nerve center-pituitary-adrenal axis.

Barington et al., [60] the impact of ghrelin on the thyroid could be because of an energy saving technique in which the orexigenic impact of ghrelin along with the decreased metabolismprompts a less catabolic state. This is as per the reverse connection between thyroid chemicals and ghrelin found in patients with hyperthyroidism [61, 62] just as the repressing impact of ghrelin on the HPT axis shown in several in vivo studies [43, 44, 63].

**Conclusions**

Ghrelin peptide hormone produce by different tissues and it has been shown to have potential effects on the body weight and thyroid hormone which may be due to the direct effects on the hypothalamus-pituitary-thyroid axis.

**Acknowledgement**

We would like to convey our gratitude and appreciation for Lec. Sumayah Faruq Kasim's invaluable aid in re-amending and crafting phrases to avoid plagiarism.

**Conflict of Interest:** The authors state that there is no conflict of interest.

**References**

1. Seo, G. H., Kim, T. H., and Chung, J. H. (2018). Antithyroid drugs and congenital malformations: a nationwide Korean cohort study. *Annals of internal medicine, 168*(6), 405-413.

2. AL-Saeed, M. H., and Al-Rufaei, I. A. (2018). Ameliorative effect of selenium on
reproductive efficiency in adult male rats with thyroid disturbance. *Bas. J. Vet. Res, 17*(1), 21-35.

3. Alkalby, J. M., and Alzerjawi, S. J. (2013). Effect of propylthiouracil-induced hypothyroidism on reproductive efficiency of adult male rats. *Bas. J. vet. Res, 12*(2), 113-121.

4. Quiñones, M., Fernø, J., and Al-Massadi, O. (2020). Ghrelin and liver disease. *Reviews in Endocrine and Metabolic Disorders, 21*(1), 45-56.

5. Akki, R., Raghay, K., and Errami, M. (2021). Potentiality of ghrelin as antioxidant and protective agent. *Redox Report, 26*(1), 71-79.

6. Raghay, K., Akki, R., Bensaid, D., and Errami, M. (2020). Ghrelin as an anti-inflammatory and protective agent in ischemia/reperfusion injury. *Peptides, 124*, 170226.

7. Ribeiro, L. F., Catarino, T., Carvalho, M., Cortes, L., Santos, S. D., Opazo, P. O., Ribeiro, L.R., Oliveira, R., Choquet, D., Esteban, J.A., Peça, J., Luísa, A., and Carvalho, A. L. (2021). Ligand-independent activity of the ghrelin receptor modulates AMPA receptor trafficking and supports memory formation. *Science signaling, 14*(670).

8. Kojima, M., Hamamoto, A., and Sato, T. (2016). Ghrelin O acyltransferase (GOAT), a specific enzyme that modifies ghrelin with a medium-chain fatty acid. *The Journal of Biochemistry, 160*(4), 189-194.

9. Seyhanli, E. S., Lok, U., Gulacti, U., Buyukaslan, H., Atescelik, M., Yildiz, M., Onur, M.R., Goktekin, M.C., and Aydin, S. (2015). Assessment of serum and urine ghrelin levels in patients with acute stroke. *International journal of clinical and experimental medicine, 8*(1), 722.

10. Asakawa, A., Inui, A., Kaga, T., Katsuura, G., Fujimiya, M., Fujino, M. A., and Kasuga, M. (2003). Antagonism of ghrelin receptor reduces food intake and body weight gain in mice. *Gut, 52*(7), 947-952.

11. Wren, A. M., Small, C. J., Abbott, C. R., Dhillon, W. S., Seal, L. J., Cohen, M. A., Rachel, L., Taheri, B.S., Sarah, A., Stanley, M. A., and Bloom, S. R. (2001). Ghrelin causes hyperphagia and obesity in rats. *Diabetes, 50*(11), 2540-2547.
alloxan. *Basrah Journal of Veterinary Research, 18*(2), 208-233.

17. Ma, H; Shieh, K. and Lee, S. (2006). Study of ELISA Technique. *Nat. Scie.*4(2):36-37.

18. Kicklighter, E. and Norman, R. (1989) *Chlin. Chem.*43,658-660.

19. Kim, S. M., Kim, S. C., Chung, I. K., Cheon, W. H., and Ku, S. K. (2012). Antioxidant and protective effects of Bupleurum falcatum on the L-thyroxine-induced hyperthyroidism in rats. *Evidence-Based Complementary and Alternative Medicine.*

20. Ríos-Prego, M., Anibarro, L., and Sánchez-Sobrino, P. (2019). Relationship between thyroid dysfunction and body weight: a not so evident paradigm. *International journal of general medicine,* 12, 299.

21. Greenlund, L. J., Nair, K. S., and Brennan, M. D. (2008). Changes in body composition in women following treatment of overt and subclinical hyperthyroidism. *Endocrine Practice,* 14(8), 973-978.

22. Delporte, C. (2013). Structure and physiological actions of ghrelin. *Scientifica.*

23. Akalu, Y., Molla, M. D., Dessie, G., and Ayelign, B. (2020). Physiological effect of ghrelin on body systems. *International journal of endocrinology,* 2020.

24. Zakhari, J. S., Zorrilla, E. P., Zhou, B., Mayorov, A. V., and Janda, K. D. (2012). Oligoclonal antibody targeting ghrelin increases energy expenditure and reduces food intake in fasted mice. *Molecular pharmaceutics,* 9(2), 281-289.

25. Mihalache, L., Gherasim, A., Nîţă, O., Ungureanu, M. C., Pădureanu, S. S., Gavril, R. S., and Arhire, L. I. (2016). Effects of ghrelin in energy balance and body weight homeostasis. *Hormones,* 15(2), 186-196.

26. Tsubone, T., Masaki, T., Katsuragi, I., Tanaka, K., Kakuma, T., and Yoshimatsu, H. (2005). Ghrelin regulates adiposity in white adipose tissue and UCP1 mRNA expression in brown adipose tissue in mice. *Regulatory peptides,* 130(1-2), 97-103.

27. Pfluger, P. T., Castañeda, T. R., Heppner, K. M., Strassburg, S., Kruthaupt, T., Chaudhary, N., Halem, H., Culler, M. D., Datta, R., Burget, L., Tschöp, M. H., Nogueiras, R., and Perez-Tilve, D. (2011). Ghrelin, peptide YY and their hypothalamic targets differentially regulate spontaneous physical activity. *Physiology & behavior,* 105(1), 52-61.

28. Yasuda, T., Masaki, T., Kakuma, T., and Yoshimatsu, H. (2003). Centrally administered ghrelin suppresses sympathetic nerve activity in brown adipose tissue of rats. *Neuroscience letters,* 349(2), 75-78.

29. Giovambattista, A., Gaillard, R. C., and Spinedi, E. (2007). Ghrelin gene-related peptides modulate rat white adiposity. *Vitamins & Hormones,* 77, 171-205.

30. Fernandez, G., Cabral, A., Cornejo, M. P., De Francesco, P. N., Garcia-Romero, G., Reynaldo, M., and Perello, M. (2016). Des-acyl ghrelin directly targets the arcuate nucleus in a ghrelin-receptor independent manner and impairs the orexigenic effect of ghrelin. *Journal of neuroendocrinology,* 28(2).

31. Al Massadi, O., López, M., Tschöp, M., Diéguez, C., and Nogueiras, R. (2017). Current understanding of the hypothalamic ghrelin pathways inducing appetite and adiposity. *Trends in neurosciences,* 40(3), 167-180.

32. Perez-Tilve, D., Heppner, K., Kirchner, H., Lockie, S. H., Woods, S. C., Smiley, D. L., Tschöp, M., and Pfluger, P. (2011). Ghrelin-induced adiposity is independent of orexigenic effects. The FASEB Journal, 25(8), 2814-2822.
33. Skibicka, K. P., and Dickson, S. L. (2013). Enteroendocrine hormones—central effects on behavior. *Current opinion in pharmacology, 13*(6), 977-982.

34. Betley, J. N., Xu, S., Cao, Z. F. H., Gong, R., Magnus, C. J., Yu, Y., and Sternson, S. M. (2015). Neurons for hunger and thirst transmit a negative-valence teaching signal. *Nature, 521*(7551), 180-185.

35. St-Pierre, D. H., Karelis, A. D., Cianflone, K., Conus, F., Mignault, D., Rabasa-Lhoret, R., St-Onge, M., Tremblay-Lebeau, A., and Poehlman, E. T. (2004). Relationship between ghrelin and energy expenditure in healthy young women. *The Journal of Clinical Endocrinology & Metabolism, 89*(12), 5993-5997.

36. Zhang, W., Majumder, A., Wu, X., and Mulholland, M. W. (2009). Regulation of food intake and body weight by recombinant proghrelin. *American Journal of Physiology-Endocrinology and Metabolism, 297*(6), E1269-E1275.

37. Sahoo, D. K., Roy, A., and Chainy, G. B. (2008). Protective effects of vitamin E and curcumin on L-thyroxine-induced rat testicular oxidative stress. *Chemico-biological interactions, 176*(2-3), 121-128.

38. Messarah, M., Boumendjel, A., Chouabia, A., Klibet, F., Abdennour, C., Boulakoud, M. S., and El Feki, A. (2010). Influence of thyroid dysfunction on liver lipid peroxidation and antioxidant status in experimental rats. *Experimental and Toxicologic Pathology, 62*(3), 301-310.

39. Ourique, G. M., Finamor, I. A., Saccol, E. M., Riffel, A. P., Pês, T. S., Gutierrez, K., Goncalves, P.B.D., Baldisserotto, B., Pavanato, M.A., and Barreto, K. P. (2013). Resveratrol improves sperm motility, prevents lipid peroxidation and enhances antioxidant defences in the testes of hyperthyroid rats. *Reproductive Toxicology, 37*, 31-39.

40. AL -Saeed M.H., and Aanas, A. (2017). Evaluation of the protective role of seeds oil of linumusitatissimum on oxidative stress of physiological parameters and some aspect of heart tissue in hyperthyroidism female rabbits. *Life Science Archives (LSA), 3*(2), 1035-1049.

41. Venditti, P., De Rosa, R., and Di Meo, S. (2003). Effect of thyroid state on H2O2 production by rat liver mitochondria. *Molecular and cellular endocrinology, 205*(1-2), 185-192.

42. Zamoner, A., Barreto, K. P., Wilhelm Filho, D., Sell, F., Woehl, V. M., Guma, F. C. R., Silva, F.R.M.B., and Pessoa-Pureur, R. (2007). Hyperthyroidism in the developing rat testis is associated with oxidative stress and hyperphosphorylated vimentin accumulation. *Molecular and Cellular Endocrinology, 267*(1-2), 116-126.

43. Šošić-Jurjević, B., Stevanović, D., Milošević, V., Sekulić, M., and Starčević, V. (2009). Central ghrelin affects pituitary-thyroid axis: histomorphological and hormonal study in rats. *Neuroendocrinology, 89*(3), 327-336.

44. Wren, A. M., Small, C. J., Ward, H. L., Murphy, K. G., Dakin, C. L., Taheri, S., Kennedy, A. R., Roberts, G. H., Morgan, D. G., Ghatel, M. A., and Bloom, S. R. (2000). The novel hypothalamic peptide ghrelin stimulates food intake and growth hormone secretion. *Endocrinology, 141*(11), 4325-4328.

45. Fusco, A., Bianchi, A., Mancini, A., Milardi, D., Giampietro, A., Cimino, V., Porcelli, D., Romualdi, M., Guido, A., Lanzone, A. P., and De Marinis, L. (2007). Effects of ghrelin administration on endocrine and metabolic parameters in obese women with polycystic ovary syndrome. *Journal of endocrinological investigation, 30*(11), 948-956.
46. Laron, Z., Frenkel, J., Gil-Ad, L., Klinger, B., Lubin, E., Wuthrich, P., Boutignon, F., Lengerts, V., and Deghenghi, R. (1994). Growth hormone releasing activity by intranasal administration of a synthetic hexapeptide (hexarelin). *Clinical endocrinology*, 41(4), 539-541.

47. Rahim, A., O’Neill, P. A., and Shalet, S. M. (1999). The effect of chronic hexarelin administration on the pituitary–adrenal axis and prolactin. *Clinical endocrinology*, 50(1), 77-84.

48. Cassoni, P., Papotti, M., Catapano, F., Ghe, C., Deghenghi, R., Ghigo, E., and Muccioli, G. (2000). Specific binding sites for synthetic growth hormone secretagogues in non-tumoral and neoplastic human thyroid tissue. *Journal of Endocrinology*, 165(1), 139-146.

49. Volante, M., Allia, E., Fulcheri, E., Cassoni, P., Ghigo, E., Muccioli, G., and Papotti, M. (2003). Ghrelin in fetal thyroid and follicular tumors and cell lines: expression and effects on tumor growth. *The American journal of pathology*, 162(2), 645-654.

50. Park, Y. J., Lee, Y. J., Kim, S. H., Joung, D. S., Kim, B. J., So, I., Park, D.J., and Cho, B. Y. (2008). Ghrelin enhances the proliferating effect of thyroid stimulating hormone in FRTL-5 thyroid cells. *Molecular and cellular endocrinology*, 285(1-2), 19-25.

51. Kordi, F., and Khazali, H. (2015). The effect of ghrelin and estradiol on mean concentration of thyroid hormones. *International journal of endocrinology and metabolism*, 13(1).

52. Kamegai, J., Tamura, H., Shimizu, T., Ishii, S., Sugihara, H., and Wakabayashi, I. (2001). Chronic central infusion of ghrelin increases hypothalamic neuropeptide Y and Agouti-related protein mRNA levels and body weight in rats. *Diabetes*, 50(11), 2438-2443.

53. Legradi, G., and Lechan, R. M. (1999). Agouti-related protein containing nerve terminals innervate thyrotropin-releasing hormone neurons in the hypothalamic paraventricular nucleus. *Endocrinology*, 140(8), 3643-3652.

54. Fekete, C., Kelly, J., Mihály, E., Sarkar, S., Rand, W. M., Légrádi, G., Emerson, C. H., and Lechan, R. M. (2001). Neuropeptide Y has a central inhibitory action on the hypothalamic-pituitary-thyroid axis. *Endocrinology*, 142(6), 2606-2613.

55. Fekete, C., Légrádi, G., Mihály, E., Huang, Q. H., Tatro, J. B., Rand, W. M., Emerson, C. H., and Lechan, R. M. (2000). α-Melanocyte-stimulating hormone is contained in nerve terminals innervating thyrotropin-releasing hormone-synthesizing neurons in the hypothalamic paraventricular nucleus and prevents fasting-induced suppression of prothyrotropin-releasing hormone gene expression. *Journal of Neuroscience*, 20(4), 1550-1558.

56. Sakurazawa, N., Mano-Otagiri, A., Nemoto, T., and Shibasaki, T. (2013). Effects of intracerebroventricular ghrelin on food intake and Fos expression in the arcuate nucleus of the hypothalamus in female rats vary with estrous cycle phase. *Neuroscience letters*, 541, 204-208.

57. Jo, Y. H., and Chua Jr, S. (2009). Transcription factors in the development of medial hypothalamic structures. *American Journal of Physiology-Endocrinology and Metabolism*, 297(3), E563-E567.

58. Giordano, R., Picu, A., Broglio, F., Bonelli, L., Baldi, M., Berardelli, R., Ghigo, E., and Arvat, E. (2004). Ghrelin, hypothalamus-pituitary-adrenal (HPA)

59. Jaszberenyi, M., Bujdoso, E., Bagosi, Z., and Telegdy, G. (2006). Mediation of the behavioral, endocrine and thermoregulatory actions of ghrelin. *Hormones and
behavior, 50(2), 266-273. axis and Cushing’s syndrome. Pituitary, 7(4), 243-248.

60. Barington, M., Brorson, M. M., Hofman-Bang, J., Rasmussen, Å. K., Holst, B., and Feldt-Rasmussen, U. (2017). Ghrelin-mediated inhibition of the TSH-stimulated function of differentiated human thyrocytes ex vivo. PLoS One, 12(9), e0184992.

61. Riis, A. L. D., Hansen, T. K., Møller, N., Weeke, J., and Jørgensen, J. O. L. (2003). Hyperthyroidism is associated with suppressed circulating ghrelin levels. The Journal of Clinical Endocrinology & Metabolism, 88(2), 853-857.

62. Ruchala, M., Gurgul, E., Stangierski, A., Wrotkowska, E., and Moczko, J. (2014). Individual plasma ghrelin changes in the same patients in hyperthyroid, hypothyroid and euthyroid state. Peptides, 51, 31-34.

63. Mahmoudi, F., Mohsennezhad, F., Khazali, H., and Ehtesham, H. (2011). The effect of central injection of ghrelin and bombesin on mean plasma thyroid hormones concentration. Iranian journal of pharmaceutical research: IJPR, 10(3), 627.
التأثير التحسيني لهرمون الكرلتين على هرمونات الغدة الدرقية ووزن الجسم في ذكر الجرذان المصاب بفرط نشاط الغدة الدرقية

*فؤاد زيدان خمزة و ** منى حميد السيد

فرع الفسلجة والإدبيات والكيمياء، كلية الطب البيطري، جامعة الكوفة – النجف، العراق

فرع الفسلجة والإدبيات والكيمياء، كلية الطب البيطري، جامعة البصرة – البصرة، العراق

الخلاصة

الهدف من الدراسة هو تقييم التأثير المعزز للكرلتين على وزن الجسم وهرمونات الغدة الدرقية في ذكر الجرذان بعد إحداث فرط نشاط الغدة الدرقية بواسطة ليفوثيروكسجين (L-T4). تم تقسيم الفئران (95 ذكر) إلى مجموعتين. تتكون المجموعة الأولى من 25 ذكر جرذان تم إعطاؤهم محلول ملحي طبيعي لمدة 30 يوماً تحت الجلد، وتم تقسيمهم كمجموعة سيطرة. بينما تم إعطاء في الفئران ليفوثيروكسجين 500 جم/كمجم تحت الجلد لفترة 30 يوماً لاستحداث فرط نشاط الغدة الدرقية. بعد الاستعداد تم تقسيمهم إلى 4 مجموعات على النحو التالي: المجموعة الأولى كانت المجموعة السيطرة، المجموعة الثانية كانت ذكور الجرذان أُعطِيت الكرلتين بجرعة (0.5 نانومول/100 ميكرولتر من محلول ملحي) لمدة 30 يومًا تحت الجلد، والمجموعة الرابعة كانت ذكور الجرذان المصابون بفرط نشاط الغدة الدرقية والتي تم إعطاؤها الكرلتين بجرعة (2 نانومول/100 ميكرولتر من محلول ملحي) لمدة 30 يومًا تحت الجلد. أظهرت النتائج عدم وجود فرق معنوي في الوزن الأولي في جميع المجموعات التي تمت ملاحظتها، بينما انخفض وزن الجسم النهائي في مجموعة فرط نشاط الغدة الدرقية معوية مع مجموعة السيطرة. من ناحية أخرى، أظهرت النتائج انخفاض معنوي في زيادة وزن الجسم لدى ذكر الجرذان المصابون بفرط نشاط الغدة الدرقية مقارنة بالكرلتين مقارنة بمجموعة فرط نشاط الغدة الدرقية معوية مع مجموعة السيطرة. بينما لوحظت النتائج زيادة معنوية في وزن الجسم النهائي وزيادة وزن الجسم في جميع الفئران المكَّالَة بالكرلتين مقارنة بمجموعة فرط نشاط الغدة الدرقية معوية مع مجموعة السيطرة. في الدوام، اَنتُخِفَت المجموعة T3 TSH T4 T3 و TSH T4 في المصل والمحلول مع المجموعة السيطرة. أما الكرلتين في تراجع الفئران في مجموعة فرط نشاط الغدة الدرقية TSH T4 T3 و T4 في المصل والمحلول مع الكرلتين مقارنة بالمستوى الأولي في جميع الفئران. بينما لم يلاحظ انخفاض معنوي في تراكيز هرمون جلوكستروجين في جميع الفئران. نلاحظ انخفاض كبير في مستوى T3 T4 في المصل في جميع الفئران مع الكرلتين مقارنة بمستوى الفئران في المصل مع الكرلتين. هرمون جلوكستروجين هو البديل وقد ثبت أن له تأثيرات على وزن الجسم، وهرمون الغدة الدرقية.